Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

Abstract The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), we analyzed RNA-sequencing in biopsies from men trea...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A. Yates, Chao Zhang, Eva Rodansky, Dhruv Khokhani, Diana Flores, Zhi Duan, Yi Zhang, Shaadi Tabatabaei, Rachel Slottke, Shangyuan Ye, Primo Lara, Adam Foye, Charles J. Ryan, David A. Quigley, Jiaoti Huang, Rahul Aggarwal, Robert E. Reiter, Max S. Wicha, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Owen N. Witte, Joshua M. Stuart, George V. Thomas, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2025-07-01
Saila:	npj Precision Oncology
Sarrera elektronikoa:	https://doi.org/10.1038/s41698-025-01002-8
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!